ESMO updates renal cancer guidelines

  • European Society for Medical Oncology
  • 26 Feb 2020

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The European Society for Medical Oncology (ESMO) has issued an update to its 2019 guidelines listing new therapies/indications in renal cell carcinoma.

Key updates

  • Pembrolizumab+axitinib in treatment-naive patients with advanced disease:
    • Phase 3 KEYNOTE-426 trial reported an absolute PFS gain of 4 months.
    • PFS: HR, 0.69 (95% CI, 0.57-0.84).
    • OS: HR, 0.53 (95% CI, 0.38-0.74).
  • Nivolumab in previously treated patients:
    • Phase 3 Checkmate 025 trial showed absolute OS gain of 5.4 months vs everolimus.
    • OS: HR, 0.73 (95% CI, 0.57-0.93).
  • Cabozantinib in patients previously treated with vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors:
    • Phase 3 METEOR trial showed OS gain of 4.9 months vs everolimus.
    • OS: HR, 0.66 (95% CI, 0.53-0.83).
  • Lenvatinib+everolimus in patients previously treated with VEGF-targeted therapy:
    • Phase 2 study.
    • OS gain: 10.1 months vs everolimus.
  • Nivolumab+ipilimumab in treatment-naive patients:
    • Phase 3 Checkmate 214: absolute OS gain of 13 months vs sunitinib.
    • OS: HR, 0.66 (95% CI, 0.54-0.80).
  • Tivozanib in patients undergoing nephrectomy:
    • Phase 3 TIVO-1 trial.
    • Absolute PFS gain: 2.8 months vs sorafenib.
    • PFS: HR, 0.80 (95% CI, 0.64-0.99).
  • Avelumab+axitinib in untreated patients:
    • Phase 3 JAVELIN Renal 101.
    • Absolute PFS gain: 5.4 months vs sunitinib.
    • PFS: HR, 0.69 (95% CI, 0.56-0.84).